pI: 9.5797 |
Length (AA): 314 |
MW (Da): 34591 |
Paralog Number:
1
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 2 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
117 | 218 | 1gox (A) | 162 | 275 | 31.00 | 0.8 | 0.06 | 0.467441 | 1.29 |
166 | 277 | 3ea5 (D) | 639 | 749 | 14.00 | 0 | 0.59 | 0.614688 | -1.25 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 60-80% percentile | amastigotes, metacyclic. | Fernandes MC |
Fernandes MC | Dual Transcriptome Profiling of Leishmania-Infected Human Macrophages Reveals Distinct Reprogramming Signatures. |
Ortholog group members (OG5_129548)
Species | Accession | Gene Product |
---|---|---|
Caenorhabditis elegans | CELE_E04F6.2 | Protein E04F6.2 |
Drosophila melanogaster | Dmel_CG15120 | CG15120 gene product from transcript CG15120-RA |
Echinococcus granulosus | EgrG_000684600 | Parkin co regulated protein |
Echinococcus granulosus | EgrG_000378100 | parkin coregulated gene protein |
Echinococcus multilocularis | EmuJ_000684600 | Parkin co regulated protein |
Echinococcus multilocularis | EmuJ_000378100 | parkin coregulated gene protein |
Giardia lamblia | GL50803_15455 | E04F6.2 like protein |
Giardia lamblia | GL50803_7875 | E04F6.2 like protein |
Homo sapiens | ENSG00000112530 | PARK2 co-regulated |
Leishmania braziliensis | LbrM.25.1780 | hypothetical protein, conserved |
Leishmania braziliensis | LbrM.34.4660 | hypothetical protein, conserved |
Leishmania donovani | LdBPK_354760.1 | PACRGB |
Leishmania donovani | LdBPK_252300.1 | parkin co-regulated protein, putative |
Leishmania infantum | LinJ.35.4760 | hypothetical protein, conserved |
Leishmania infantum | LinJ.25.2300 | hypothetical protein, conserved |
Leishmania major | LmjF.25.2200 | hypothetical protein, conserved |
Leishmania major | LmjF.35.4690 | hypothetical protein, conserved |
Leishmania mexicana | LmxM.34.4690 | hypothetical protein, conserved |
Leishmania mexicana | LmxM.25.2200 | hypothetical protein, conserved |
Mus musculus | ENSMUSG00000037196 | PARK2 co-regulated |
Neospora caninum | NCLIV_054560 | hypothetical protein, conserved |
Onchocerca volvulus | OVOC6184 |
|
Schistosoma japonicum | Sjp_0096750 | similar to Uncharacterized protein C4orf28, putative |
Schistosoma mansoni | Smp_035500 | hypothetical protein |
Schmidtea mediterranea | mk4.000166.25 | |
Schmidtea mediterranea | mk4.000483.00 | |
Trypanosoma brucei gambiense | Tbg972.3.2290 | hypothetical protein, conserved |
Trypanosoma brucei gambiense | Tbg972.9.5720 | hypothetical protein, conserved |
Trypanosoma brucei | Tb927.3.2310 | PACRGA |
Trypanosoma brucei | Tb927.9.9940 | PACRGB |
Trypanosoma congolense | TcIL3000_0_39200 | PACRGB |
Trypanosoma cruzi | TcCLB.510731.20 | hypothetical protein, conserved |
Trypanosoma cruzi | TcCLB.508479.270 | hypothetical protein, conserved |
Trypanosoma cruzi | TcCLB.506887.20 | hypothetical protein, conserved |
Toxoplasma gondii | TGME49_310480 | flagellar/basal body protein, PACRG family protein |
Trichomonas vaginalis | TVAG_377800 | conserved hypothetical protein |
Trichomonas vaginalis | TVAG_062600 | conserved hypothetical protein |
Trichomonas vaginalis | TVAG_342930 | conserved hypothetical protein |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.3.2310 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (3 days) | alsford |
Tb927.3.2310 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (6 days) | alsford |
Tb927.3.2310 | Trypanosoma brucei | significant gain of fitness in procyclic forms | alsford |
Tb927.3.2310 | Trypanosoma brucei | significant loss of fitness in differentiation of procyclic to bloodstream forms | alsford |
Tb09.211.1470 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (3 days) | alsford |
Tb09.211.1470 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (6 days) | alsford |
Tb09.211.1470 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb09.211.1470 | Trypanosoma brucei | significant gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
TGME49_310480 | Toxoplasma gondii | Probably non-essential | sidik |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.